Description
Tesamorelin 10 mg Genheal — tesamorelin from Genheal at 10 mg. Stabilised GHRH analog. Clinically approved for HIV-associated visceral fat reduction. Drives endogenous GH pulses without exogenous HGH side-effects.
Key Benefits
- Growth-hormone-releasing peptide — triggers endogenous GH
- GHRP-6: strong hunger stimulation (useful for bulk); GHRP-2: less hunger
- Elevates prolactin and cortisol modestly (vs clean ipamorelin)
- Stacks with GHRH analogues for pulse amplification
- SubQ, 2–3× daily
- Each unit dosed at 10 mg — see Recommended Dosage below for protocol-specific intake
Recommended Dosage
Research dosing: 100–200 mcg 2–3× daily SubQ. Pre-meal dosing capitalises on GHRP-6’s hunger effect for mass protocols; pre-bed for GH-pulse amplification. Cycles 8–12 weeks.
How It Works
Growth-hormone-releasing peptides (GHRP-2 or GHRP-6). Bind the GHS receptor on the pituitary, triggering GH release. Less selective than ipamorelin — also elevate cortisol and prolactin modestly.
Pharmacokinetics
Plasma half-life approximately 30 minutes. Multiple daily doses required. Reconstituted stable 4–6 weeks refrigerated.
Potential Side Effects
GHRP-6: aggressive hunger within 30 minutes of injection (bug or feature). Both raise cortisol and prolactin modestly — not an issue short-term but worth monitoring on long runs. Injection-site reactions possible.
Cycle & Stacking Guide
8–12 weeks. Stack with CJC-1295 for synergy. Choose GHRP-6 for mass protocols (hunger), GHRP-2 for cutting or recomp (cleaner).
Manufacturer Notes
Genheal specialises in HGH, peptides, and research compounds. Lyophilised products ship with standard cold-chain documentation.
Storage & Handling
Store at recommended temperature (15–25°C; peptides and HGH at 2–8°C after reconstitution). Protect from light and moisture. Keep out of reach of children. For research and educational purposes only.
Reviews
There are no reviews yet.